NCT04258995View on ClinicalTrials.gov

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

September 15, 2020

Study Completion Date

September 15, 2020

Conditions
Group B Streptococcal Infections
Interventions
BIOLOGICAL

Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)

2 formulations at 1 dose level

Trial Locations (4)

30281

Clinical Research Atlanta, Stockbridge

40004

Kentucky Pediatric & Adult Research Inc., Bardstown

84109

J. Lewis Research, Inc./ Foothill Family Clinic South, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04258995 - A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS | Biotech Hunter | Biotech Hunter